Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Welcome to the team Hannah! ⭐️& Forever part of our family?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by jopatcloon Jan 21, 2025 7:46am
23 Views
Post# 36412924

RE:Welcome to the team Hannah! ⭐️& Forever part of our family?

RE:Welcome to the team Hannah! ⭐️& Forever part of our family?Interesting post on Linkedin & ?

Welcome to the team Hannah! & Forever part of our family?

Accder mon site web
2 h •
( Interesting see Edwards Lifesciences Investment in this space is robust and expected to continue. Edwards Lifesciences acquired four companies last year alone in StructuralHeart. Valve repair and replacement are the largest volume within cardiovascular procedures overall, and growing. )

 & remember post Hugh
The scope of our business plan has expanded to include investigating the utility of VMS+ to support valve procedures. It's encouraging to note that Ventripoint technology and products touch on two of F&S's top 10 growth opportunities in Healthcare and Life Sciences for 2025. More to come ...

Accder mon site web
Where there is a significant unmet market need, in a market that people care about, investment, and a strong team, opportunities abound.

Case in point: Anteris Technologies.

Cardiovascular structural heart market, multibillion dollar and growing. Existing technologies leave significant clinical gap and tremendous room for better patient outcomes.

Structural heart disease impacts children, congenital heart disease is the most common birth defect in kids. Aortic Stenosis is a multibillion dollar market and growing in the double digits. All ages and walks of life can be affected.

Investment in this space is robust and expected to continue. Edwards Lifesciences acquired four companies last year alone in StructuralHeart. Valve repair and replacement are the largest volume within cardiovascular procedures overall, and growing.

Strong leadership. A team that has the experience to understand the market drivers, while holding the vision of tomorrow's possibilities.

Thanks to David St. Denis, COO at Anteris, for joining me on TechTalks.
The Mullings Group One60Studios Dragonfly - A TMG Company Hailey Schuck Dominic Lynch aorticstenosis valverepair CHD cardiovascular

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities